PET imaging for guiding T-NK cell lymphoma treatment
Part of Cancer, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This study uses a special PET scan to look for a protein called Granzyme B in your body, which may help predict how well treatment will work in T-NK cell lymphoma. It aims to see if this imaging can guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with T-NK cell lymphoma (a type of lymphoma that affects certain immune cells)
- You are either newly diagnosed and have not yet received treatment, or your lymphoma has come back or not responded to treatment and you are about to start immunotherapy
- You have not had any prior anti-tumor therapy (like chemotherapy or radiation) before joining this study
- You have no history of other cancers
- You are willing to provide your medical records and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses artificial intelligence to analyze PET/CT scans from people with T-NK cell lymphoma. It aims to improve diagnosis, predict how well treatment will work, and forecast outcomes.
This trial studies whether special imaging with PET/MR can help stage (find the extent of) and evaluate treatment effectiveness in people newly diagnosed with NK/T-cell lymphoma. It may help doctors choose the right treatment plan and track how well therapy is working.
This trial tests a new type of PET scan (Granzyme B-PET) to see if it can predict how well immunotherapy will work for people with triple-negative breast cancer that has spread. If it works, doctors might be able to tell sooner whether treatment is helping.
This trial uses a special PET scan to see if a protein called Granzyme B can predict how well immunotherapy will work for people with DLBCL. It aims to help doctors know earlier if treatment is effective.
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
This trial uses a special scan (68Ga-grazytracer PET) to see how well immunotherapy works for stage III non-small cell lung cancer before surgery or radiation. It aims to help doctors choose the best treatment for you.
Hear when a new T-NK Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.